Find treatment
The FDA approved histotripsy for the treatment of liver tumors in October 2023. The clinical histotripsy system, Edison, is produced by HistoSonics, a company with deep ties to the University of Michigan. Edison treatment systems are now available in 18 states, the United Arab Emirates and Hong Kong.
Clinical Trials
A multi-center clinical trial is ongoing to treat patients with renal tumors in the U.S. and Europe (Hope4Kidney), and a new trial is underway in Spain for pancreatic tumors. More trials are planned for the future. Learn more in the HistoSonics Clinical Trials Portfolio.
Renal cancer: #HOPE4KIDNEY trial
There is an ongoing multi-center trial on non-invasive treatment of renal tumor using histotripsy in the U.S. and Europe. Renal cancer patients interested in participating in a histotripsy clinical trial, please contact Dr. Joe Herman at joe.herman@histosonics.com.
Pancreatic cancer: #Gannon trial
Phase I clinical trial on non-invasive treatment of pancreatic tumors using histotripsy is recruiting in Spain. Only patients with pancreatic tumors located in Spain are being recruited for this Phase I trial focused on investigating safety.